It seems hardly any of the new patients were assessable.
It will be interesting to see if they have enough data for a shot at phase 2 being approved as a registrational study.
Don't see any reference to it. Though it seems that there has been a tempering of over exuberantly forward looking statements.
Still it looks like a marked improvement on SOC.
I personally prefer the more reality balanced and fact based communication style. Let the data talk and leave the supposition to oneself.
Ann: PTX-100 Ph1b results show excellent safety & efficacy in TCL, page-20
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.001(2.44%) |
Mkt cap ! $33.01M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.2¢ | 4.0¢ | $34.23K | 833.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 200294 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 10830 | 1 |
View Market Depth
| Last trade - 15.06pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
4.2¢ |
Change
0.001 ( 2.44 %) |
||||
| Open | High | Low | Volume | ||
| 4.0¢ | 4.2¢ | 4.0¢ | 202233 | ||
| Last updated 15.24pm 18/06/2024 ? | |||||
| PTX (ASX) Chart |